Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Breaking News, Don’t Miss, Health & Wellness, Industry

4 Nov 2024

SoundSelf’s Wefunder Campaign: Bringing Digital Psychedelics to Mental Health Providers

SoundSelf, the groundbreaking digital therapeutics company, is launching a community investment campaign on Wefunder. This Austin-based innovator aims to revolutionize mental health care by using immersive technology to support mental...

By Madison Roberts

Breaking News, Press Releases

15 Oct 2024

Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003

New preclinical results showcase EB-003’s ability to target serotonergic receptors while minimizing risks of cardiovascular and CNS side effects, advancing its potential as a non-hallucinogenic treatment for mental health disorders....

By Madison Roberts

Breaking News

25 Sep 2024

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Enveric Biosciences presented promising preclinical data on their lead drug candidate, EB-003, at the 7th Neuropsychiatric Drug Summit. This non-hallucinogenic, neuroplastogenic DMT analog demonstrated significant reductions in anxiety and depression...

By Madison Roberts

Breaking News

13 Aug 2024

FDA Rejected MDMA-Assisted PTSD Therapy: Psychedelic Industry Responds

The FDA's recent rejection of MDMA-assisted therapy for PTSD has sparked significant reactions from the psychedelic and mental health communities. While the decision is seen as a setback, industry leaders...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Culture

2 Aug 2024

Kathryn A. Walker Unveils New Book ‘Inflamed: Theory’ on Kindle and Amazon

In her latest book, "Inflamed: Theory," Kathryn A. Walker, CEO of Revitalist Lifestyle and Wellness Ltd., challenges traditional views on mental health. Available on Kindle and Amazon, this groundbreaking publication...

By Madison Roberts

Culture, Health & Wellness

25 Jul 2024

Exploring the Nexus of Cannabis Use and Mindfulness in Young Adults

In recent years, the intersection of mental health practices and substance use has garnered significant attention, particularly among young adults navigating the complexities of modern life. The Herbal Heart Study,...

By Madison Roberts

Press Releases

25 Jul 2024

Enveric Biosciences Announces Promising Preclinical Results for EB-003

Enveric Biosciences has announced promising preclinical results for their novel drug candidate, EB-003. The findings highlight the drug’s potential for oral administration and significant brain exposure in rodent models. These...

By Madison Roberts

Press Releases

16 Jul 2024

Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogens for neuropsychiatric disorders, and Aries Science & Technology, a developer of encapsulation technologies, have announced a licensing agreement...

By Madison Roberts

Industry

15 Jul 2024

Integrating SoundSelf in Ketamine Clinics: Enhancing Patient Outcomes Through Immersive Technology

Ketamine clinics are revolutionizing mental health treatment for those with resistant depression and other conditions. Integrating SoundSelf, an immersive biofeedback and neurostimulation technology, can further enhance these therapies. This article...

By Madison Roberts

Follow us on social

Latest News

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads